SCHEMBL15470534

SCHEMBL15470534

O=c1c2cc(Br)ccc2oc2c(F)cc(I)cc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRP O00591 5/20 0.43
GABRD O14764 5/20 0.43
GABRA1 P14867 5/20 0.43
GABRB1 P18505 5/20 0.43
GABRG2 P18507 5/20 0.43
GABRB3 P28472 5/20 0.43
GABRA5 P31644 5/20 0.43
GABRA3 P34903 5/20 0.43
GABRA2 P47869 5/20 0.43
GABRB2 P47870 5/20 0.43
GABRA4 P48169 5/20 0.43
GABRE P78334 5/20 0.43
GABRA6 Q16445 5/20 0.43
GABRG1 Q8N1C3 5/20 0.43
GABRG3 Q99928 5/20 0.43
GABRQ Q9UN88 5/20 0.43
PIM1 P11309 5/20 0.41
CSNK2A2 P19784 5/20 0.41
CSNK2B P67870 5/20 0.41
PIM3 Q86V86 4/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2372207 0.80 GABRP (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2000388 0.80 PIM1 (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2370587 0.80 MAPT (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL8515753 0.77 MAPT (0.50) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2588529 0.76 PIM1 (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29416622 0.76 PIM1 (0.58) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL2000612 0.75 GABRP (0.49) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL19513555 0.74 GABRP (0.42) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL12468860 0.74 NPC1 (0.41) KMT2ASMN1; SMN2KDM4ENPC1MAPT
SCHEMBL10170969 0.73 CYP11B1 (0.44) PIM1CSNK2A2CSNK2BCSNK2A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012446-B2 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2015-04-21 US disclosed
US-9012446-B2 Amino-oxazines and amino-dihydrothiazine compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2015-04-21 US disclosed
US-20140045828-A1 AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. 2014-02-13 US disclosed
US-20140045828-A1 AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045828-A1 AMINO-OXAZINES AND AMINO-DIHYDROTHIAZINE COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, APP, BACE2 GABRP 1406/4885GABRD 1654/4885GABRA1 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.